How Modified Insulin Becomes a Target in Type 1 Diabetes

In Type 1 diabetes, the immune system mistakenly attacks insulin-producing beta cells. Scientists have long known that insulin itself is one of the targets of these attacks, but something didn't add up: the natural form of insulin is not very effective at triggering an immune response. This raises an important question: if native insulin is poorly antigenic—meaning it doesn't activate the immune system easily—why is it such a prominent target in Type 1 diabetes?

The answer may lie not in insulin itself, but in how insulin is modified after it's made. A growing body of research suggests that post-translational modifications—chemical changes that happen to proteins after they're synthesized—can dramatically change how recognizable insulin is to the immune system.

Inside beta cells, insulin doesn't exist alone. It's stored in secretory granules alongside other proteins, and these compartments contain powerful enzymes. One of these enzymes, cathepsin D (a protease that breaks down proteins), appears to play a key role in creating modified versions of insulin called hybrid insulin peptides (HIPs).

HIPs form when cathepsin D snips pieces of insulin and joins them to other granule proteins through a process called transpeptidation. In this study, researchers found that cathepsin D has a specific preference: it tends to cleave the insulin B-chain (one of two chains that make up mature insulin) right after tyrosine 16, an amino acid that has been linked to disease in previous research.

This specificity suggests that HIP formation may not be random or accidental. Instead, the enzyme's preference for cutting at this particular spot may create modified insulin versions that are tailor-made to trigger immune recognition.

To test whether HIPs containing the insulin B9-16 fragment become more antigenic than native insulin, researchers created a panel of different HIPs and exposed immune cells from diabetic mice to them. Using an ELISPOT assay (a test that measures immune cell activation), they found elevated inflammatory responses to several of these modified peptides.

Among the HIPs tested, one stood out: a fusion between the insulin B9-16 fragment and C-peptide (another part of the proinsulin molecule) called 2.40HIP. This peptide was recognized by PD12-2.40, a diabetogenic CD4 T cell clone—a type of immune cell known to cause diabetes. The findings show that this particular insulin sequence becomes dramatically more antigenic when modified through HIP formation.

This discovery identifies a previously unrecognized antigenic region within the insulin B9-23 sequence and demonstrates a clear mechanism by which post-translational modification makes insulin a stronger target for immune attack.

These results provide new insight into a critical question: why does the immune system attack beta cells in Type 1 diabetes? Rather than targeting native insulin directly, the immune system may be responding to modified versions of insulin that are created naturally within beta cells. This changes how scientists think about the very beginning of the disease process.

By identifying exactly which regions of insulin become antigenic after modification, and understanding the enzymes that create these modifications, researchers are building a clearer map of the events that lead to autoimmune attack. This knowledge could eventually inform new strategies for preventing or delaying Type 1 diabetes in people at genetic risk—though much more research is needed to translate these findings into clinical tools.

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.